Review of vasodilators in acute decompensated heart failure: the old and the new.

Michelle D. Carlson, Peter M Eckman

Research output: Contribution to journalReview articlepeer-review

27 Scopus citations


Despite substantial improvements in treatment for chronic heart failure, morbidity and mortality for acute decompensated heart failure (ADHF) remain high. Treatment of ADHF is focused on controlling symptoms rather than improving long-term outcomes. The vasodilators nitroglycerin (NTG) and sodium nitroprusside (SNP) have been used in ADHF for decades, but, since the development of nesiritide 10 years ago, interest in new vasodilators has grown. Therapies that improve not only hemodynamics and symptoms but also long-term outcomes are in high demand, and numerous new vasodilatory agents have been investigated, including various natriuretic peptides, soluble guanylyl cyclase agents, renin-angiotensin-aldosterone system-modifying agents, and others. A review of the literature shows that few of them rise to the challenge set by NTG and SNP.

Original languageEnglish (US)
Pages (from-to)478-493
Number of pages16
JournalJournal of cardiac failure
Issue number7
StatePublished - Jul 2013

Bibliographical note

Copyright 2020 Elsevier B.V., All rights reserved.


Dive into the research topics of 'Review of vasodilators in acute decompensated heart failure: the old and the new.'. Together they form a unique fingerprint.

Cite this